Ignyta, Inc. is a biotechnology company developing personalized medicine in cancer. They are pursuing an integrated Rx/Dx strategy of combining highly targeted drug discovery and development with companion diagnostics for patient selection. Ignyta’s goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. They plan to achieve this goal by leveraging proprietary cancer and immunology genomic and epigenomic knowledge bases to discover novel targets and deliver the next generation of targeted therapeutics accompanied by highly informative biomarkers for patient selection, treatment, and monitoring. Ignyta’s lead clinical candidate, RXDX-101, is an oral, potential first-in-class tyrosine kinase inhibitor of TrkA, ROS1, and ALK. The compound is currently being tested in patients in a Phase 1/2 clinical study. The Company intends to target approximately six unique patient populations in the Phase 2 dose expansion portion of the ongoing study to identify the most appropriate indications for later trials. Ignyta’s RXDX-102 clinical candidate is an oral, selective tyrosine kinase inhibitor of TrkA, TrkB, and TrkC currently in preclinical testing.